BioVoice News December 2017-January 2018 Issue 7 Volume 2 | Page 50

tech providers ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: cGMP manufacturing facility in Panoli, Gujarat, India, using proprietary purification technology to achieve endotoxin levels that are below required thresholds to help reduce the potential for adverse chemical reactions. For example, J.T.Baker HPLE galactose of biopharmaceutical streamline contains significantly product discovery and production and lower levels of trace development, and it eliminate metals when compared appears that variability in to standard galactose engineering and biopharma and available through reverse-engineering of pharma multicompendial carbohydrate sources. This is crucial attachment can prove a manufacturing? powerful tool in the We recently developed for biopharmaceutical manufacturers with field of biosimilars and and introduced established cell culture protein-therapeutic J.T.Baker High Purity engineering, as well as Low Endotoxin (HPLE) processes that rely on highly controlled levels helping streamline sugars to help reduce of metal in order to Food and Drug variability and Administration (FDA) streamline production reach desired yield for a target molecule. approval processes. in biopharmaceutical manufacturing. These Another way we are How is Avantor products are helping our helping to manufactured at our 50 BioVoiceNews | Dec 2017 - Jan 2018